Raloxifene in Reducing the Risk of Postmenopausal Fracture amongst Osteoporotic Subjects
Background: Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent decrease in bone mineral density (BMD) and increase in bone fragility and susceptibility to fracture. Hence; we planned the present study to assess the effect of raloxifene in reducing the risk of postmenopausal fracture amongst osteoporotic subjects.
Methods: The present study included assessment of effect of raloxifene in reducing the risk of postmenopausal fracture amongst osteoporotic subjects. A total of 120 postmenopausal women were included in the present study. All the subjects were broadly divided into two broad groups with 60 subjects in each group; Group A: Subjects who were given placebo for two years Group B: Subjects who were given raloxifene 60 mg/d for 2 years. Assessment of Risk of Postmenopausal Fracture in all the subjects was done by evaluating the bone mineral density (BMD) at two years follow-up time. All the results were compiled and assessed by SPSS software. Results: Non- significant results were obtained while comparing the adverse effects among subjects of both the study groups. Overall incidence of new vertebral fractures among subjects of group A and group B included 6 and 4 percent respectively. Significant results were obtained while comparing the incidence of new vertebral fractures among subjects of group A and group B respectively. Conclusion: Significant reduction in the risk of fractures occur under the influence of raloxifene in postmenopausal women with osteoporosis.
2. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010–2018.
3. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas.
4. NIH Consensus Development Panel on Osteoporosis Prevention,
Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy.
5. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime
osteoporosis impact. Arch Intern Med. 1991;151:2026–2032.
6. Oleksik AM, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P. Effects of the selective estrogen receptor modulator, raloxifene on the somatotropic axis insulin-glucose homeostasis. J Clin Endocrinol Metab. 2001;86:2763–
7. Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic
cells. Biochem Biophys Res Commun. 2005;328:709–720.
8. Johnell O1, Cauley JA, Kulkarni PM, Wong M, Stock JL. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless
of prior hormone therapy. J Fam Pract. 2004 Oct;53(10):789-96.
9. Ensrud KE1, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone
Miner Res. 2008 Jan;23(1):112-20.
Copyright (c) 2018 International Archives of BioMedical and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.